Advanced search×

Continuous dopaminergic therapy in Parkinson disease: time to stride back?

A Jon AJ Stoessl

Ann Neurol 68(1):3-5 (2010) PMID 20583222

DOI: 10.1002/ana.22079
Version: za2963e q8za1 q8zbc q8zc4 q8zde q8zee q8zf4 q8zgd
View PDF

Similar articles you may find interesting…

  1. Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy (3C) Study: background, rationale, and study protocol.
    Richard Haynes, Colin Baigent, and Peter Friend

    Transplantation Research 2(1):7 (2013) PMID 23641902

    BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI)...
  2. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations...
    Thomas Müller

    Expert Opin Drug Metab Toxicol (2013) PMID 23642267

    Recent experimental and clinical research has shown that A2A adenosine receptor antagonism can bring about an improvement in the motor behavior of patients with Parkinson's disease. Istradefylline , a xanthine derivative, has the longest half-life of all the currently available A2A adenosine recepto...
  3. Physical Activity Behavior Change in Persons With Neurologic Disorders: Overview and Examples From Parkinson Disease and Multiple Sclerosis.
    Terry Ellis and Robert W Motl

    J Neurol Phys Ther (2013) PMID 23632452

    We then examine the social cognitive theory as an approach to identifying the primary active ingredients for behavioral change and, hence, the targets of interventions for increasing physical activity levels. The design and efficacies of interventions based on the social cognitive theory for increas...